Revolution Medicines (RVMD) Shares Outstanding (Diluted Average) (2020 - 2026)
Revolution Medicines (RVMD) recorded quarterly Shares Outstanding (Diluted Average) of $198.1 million in Q1 2026, up 4.19% quarter-over-quarter from $190.1 million in Q4 2025, and up 5.29% on a YoY basis from $188.1 million in Q1 2025.
Revolution Medicines (RVMD) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Revolution Medicines' Shares Outstanding (Diluted Average) history runs 7 years deep, the most recent figure standing at $198.1 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Diluted Average) rose 5.29% year-over-year to $198.1 million; the TTM figure through Mar 2026 stood at $198.1 million (up 5.29% YoY), while the FY2025 annual figure was $190.1 million, up 13.35% from the prior year.
- Shares Outstanding (Diluted Average) was $198.1 million for Q1 2026 at Revolution Medicines, up from $190.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $198.1 million in Q1 2026 to a low of $74.2 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $138.1 million across 5 years, with a median of $164.7 million in 2024.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Diluted Average) increased 1.12% in 2022, then surged 73.71% in 2024.
- A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $80.6 million in 2022, then surged by 40.34% to $113.1 million in 2023, then soared by 48.24% to $167.7 million in 2024, then gained by 13.35% to $190.1 million in 2025, then rose by 4.19% to $198.1 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $198.1 million (Q1 2026), $190.1 million (Q4 2025), and $189.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 810.00 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 92.44 Mn |
| 10 | Revolution Medicines | 32.33 Bn | 32.33 Bn | - | 198.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 198.10 Mn |
| Dec 31, 2025 | 190.13 Mn |
| Sep 30, 2025 | 189.23 Mn |
| Jun 30, 2025 | 188.58 Mn |
| Mar 31, 2025 | 188.15 Mn |
| Dec 31, 2024 | 167.74 Mn |
| Sep 30, 2024 | 165.58 Mn |
| Jun 30, 2024 | 165.14 Mn |
| Mar 31, 2024 | 164.73 Mn |
| Dec 31, 2023 | 113.15 Mn |
| Sep 30, 2023 | 109.23 Mn |
| Jun 30, 2023 | 106.88 Mn |
| Mar 31, 2023 | 94.83 Mn |
| Dec 31, 2022 | 80.63 Mn |
| Sep 30, 2022 | 77.75 Mn |
| Jun 30, 2022 | 74.22 Mn |
| Mar 31, 2022 | 74.16 Mn |
| Dec 31, 2021 | 72.81 Mn |
| Sep 30, 2021 | 73.54 Mn |
| Jun 30, 2021 | 73.40 Mn |